Table 3.
Logistic regression univariate and multivariate analyses of factors predicting SARS-CoV-2 breakthrough infection after full vaccination
| Characteristics | SARS-CoV-2 infection | p value | SARS-CoV-2 infection | p value |
|---|---|---|---|---|
| Univariate OR (95% CI) |
Multivariate OR (95% CI) |
|||
| Prior COVID-19 | 0.2 (0.02–1.2) | 0.1 | ns | |
| Type of vaccine | ||||
| Moderna mRNA-1273 | 1 | |||
| Pfizer-BionTech BNT162b2 | 0.6 (0.14–2.6) | 0.5 | ||
| Adenoviral vector-based | 0.75 (0.16–3.5) | 0.7 | ||
| Age (years) | ||||
| 18–40 years | 1 | |||
| 41–60 years | 0.8 (0.32–2.1) | 0.67 | ||
| 61–70 years | 0.37 (0.12–1.18) | 0.09 | ns | |
| > 71 years | 0.49 (0.16–1.44) | 0.19 | ||
| Male sex | 1.6 (0.8–3.2) | 0.166 | ||
| Baseline disease | ||||
| ALL | 1 | |||
| AML | 1.3 (0.14–11.2) | 0.8 | ||
| MDS | 1.47 (0.16–33) | 0.7 | ||
| B-cell NHL | 0.76 (0.08–6.6) | 0.8 | ||
| T cell NHL | 3.8 (0.38–38.4) | 0.25 | ||
| Plasma cell disorders | 0.97 (0.11–8.5) | 0.9 | ||
| CLL | 1.16 (0.12–10.7) | 0.9 | ||
| HD | 2.78 (0.32–23.8) | 0.35 | ||
| cMPN | 0.65 (0.05–7.4) | 0.7 | ||
| Aplastic anemia | 0.000 | 0.99 | ||
| Non-malignant disorders | 2.6 (0.15–44.7) | 0.5 | ||
| Status disease at vaccination | ||||
| Complete remission | 1 | |||
| Partial remission | 1.47 (0.58–3.7) | 0.4 | ||
| Active disease | 0.92 (0.45–2.06) | 0.9 | ||
| Time from last treatment to COVID-19 vaccine | ||||
| Untreated | 1 | |||
| Under treatment | 0.47 (0.17–1.26) | 0.13 | ||
| > 6 months to 1 year | 1.35 (0.41–4.39) | 0.6 | ||
| ≥ 1 year | 0.58 (0.23–1.45) | 0.24 | ||
| Cell therapy | ||||
| Yes | 0.58 (0.3–1.1) | 0.1 | ns | |
| No | 1 | |||
| Allo-HSCT | 1.6 (0.82–3.4) | 0.15 | ||
| ASCT | 2.19 (0.8–5.98) | 0.12 | ||
| CAR-T | 0.00 | 0.99 | ||
| Corticosteroids at vaccination | 1.2 (0.56–2.7) | 0.59 | ||
| Daratumumab | 0.8 (0.1–6) | 0.83 | ||
| Venetoclax | 0.00 | 0.99 | ||
| Anti-CD-20 moAb | 0.57 (0.2–1.6) | 0.29 | ||
| Bruton’s TKI therapy | 1.9 (0.57–6.4) | 0.29 | ||
| TKI therapy | 0.95 (0.12–7) | 0.9 | ||
| Lenalidomide | 0.6 (0.14–2.5) | 0.48 | ||
| Ruxolitinib therapy | 0.00 | 0.99 | ||
| SCoV2-R-A negative at 3–6 weeks after 2 doses | 2.5 (1.3–4.9) | 0.007 | 2.35 (1.2–4.6) | 0.012 |
| Lymphocyte count < 0.5 × 109/L | 0.75 (0.09–5.4) | 0.75 | ||
| Lymphocyte count < 1.0 × 109/L | 1.5 (0.7–3.3) | 0.27 | ||
AL, Acute leukemia; MDS, myelodysplastic syndrome; B-cell NHL, B-cell non-Hodgkin lymphoma; MM, multiple myeloma; CLL, chronic lymphocytic leukemia; HD, Hodgkin disease; MPN, chronic myeloproliferative neoplasm; Allo-HSCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation; moAb, monoclonal antibody; TKIs, tyrosine kinase inhibitors; and SCoV2-R-A, SARS-CoV-2-reactive IgG antibodies